Basilea announces closing of previously announced transaction regarding divestment of its Chinese R&D subsidiary
Basel, Switzerland, April 01, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced the successful closing of the previously announced divestment of its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (“BPC”) to the U.S.-based custom manufacturing organization PHT International Inc. (“PHT”) for a total consideration of USD 6.3 million. Basilea has received the initial payment of USD 2.5 million and is entitled to receive additional payments of USD 3.8 million over the course of the next three years. All 72 employees of BPC and the facilities have been transferred to PHT. PHT continues to provide R&D services to Basilea through the existing site in China.
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
|Phone||+41 61 606 1102|
This press release can be downloaded from www.basilea.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Chief Executive Officer12.4.2021 18:46:17 CEST | Press release
The Board of Golar LNG has today received a resignation notice from its CEO Iain Ross. The contractual termination period is 6 months however the final duration can be prolonged or reduced upon mutual agreement. Golar LNG is currently in the final stages of closing the announced sale of its 50% interest in Hygo Energy Transition Limited (“Hygo”) and 32% interest in Golar LNG Partners LP (“GMLP”) to New Fortress Energy Inc. (“NFE”) for a total enterprise value consideration for the two companies of approximately USD 5 billion. The NFE transactions will simplify the Golar group structure, crystalize underlying value and strengthen the balance sheet. The majority of the closing conditions have been completed, including prepayment notices issued to several of GMLPs lenders. Closing of the transactions is expected shortly. The Board of Golar LNG will immediately start the process to recruit Mr. Ross’s successor. Forward-Looking Statements This press release contains forward-looking statemen
RCI Banque : 2020 ANNUAL FINANCIAL REPORT12.4.2021 18:30:00 CEST | Press release
April, 9th 2021 RCI Banque : 2020 ANNUAL FINANCIAL REPORT is now available on our website www.rcibs.com Attachment RCI BANQUE Rapport Financier Annuel 2020
The RCI Banque "2020 Annual Financial Report" is now available on the AMF website12.4.2021 18:30:00 CEST | Press release
April, 12th 2021 The RCI Banque "2020 Annual Financial Report" is now available on the AMF website. Attachment Communiqué Publication RCI Banque 2020 Annual Financial Report
Diac S.A. : 2020 ANNUAL FINANCIAL REPORT12.4.2021 18:30:00 CEST | Press release
April, 12th 2021 The DIAC "2020 Annual Financial Report " is now available. Attachment DIAC S.A Rapport Annuel Financier 2020
The DIAC group "2020 ANNUAL FINANCIAL REPORT" is now available on the AMF website12.4.2021 18:30:00 CEST | Press release
April, 12 th 2021 The DIAC S.A "2020 ANNUAL FINANCIAL REPORT" is now available on the AMF website. Attachment Communiqué Publication Rapport Financier Semestriel DIAC 2020 (GB)
Agfa-Gevaert: Share buyback program – regulated information12.4.2021 17:40:00 CEST | Press release
Mortsel, Belgium – April 12, 2021 – 5:40 p.m. CET Within the framework of the share buyback program which was announced in the press release of March 10, 2021, Agfa-Gevaert NV proceeded with the purchase of own shares on the market of Euronext Brussels. The authorization to acquire own shares was granted to the Board of Directors by the Extraordinary General Meeting of Shareholders of May 12, 2020. Agfa-Gevaert NV has requested a financial intermediary to repurchase Agfa-Gevaert shares for a maximum amount of 50.000.000 Euro on its behalf under the terms of an initial discretionary mandate agreement with validity until 31 March 2022, effective as from 1 April 2021. On April 9, 2021, the Agfa-Gevaert Group held 246,467 own shares, which represents 0,15% of the total number of shares of the Group. Detailed operations per day: DateNumber of sharesAverage price (€)Minimum price (€)Maximum price (€)Total price (€)April 1, 202154,7174.01983.96504.1500219,951.40April 6, 202128,4684.01933.9950
NOVA Chemicals Surpasses 65% Completion of its Growth Projects in Ontario, Targets 2022 Start-Up12.4.2021 17:00:00 CEST | Press release
Canadian innovation brings new premium-value, polyethylene resins for recyclable packaging to North American and global markets; The combined projects represent an investment of approximately $2.5 billion (CAD) in the community; Early equipment has been put in service; start-up will commence in late 2022 Sarnia, Ontario, April 12, 2021 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation, 1000 Seventh Avenue S.W., Calgary, Alberta, Canada T2P 5L5 www.novachemicals.com | 403.750.3600 tel | 403.269.7410 fax NOVA Chemicals Corporation (“NOVA Chemicals”) today announced its second Advanced SCLAIRTECH™ technology (AST) unit and the third phase of the Corunna Cracker Expansion Project have each safely surpassed 65% completion. The first of eight electrical substations were safely energized in March, and the company estimates that both projects will commence full start-up activities in late 2022, after the Corunna Site turnaround which is targeted for spring 2022. The new AST polyethylene unit, loc